Cited by 39Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Amyloid β-peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation

Lannfelt, Lars, Basun, Hans, Vigo-Pelfrey, Carmen, Wahlund, Lars-Olof, Winblad, Bengt, Lieberburg, Ivan, Schenk, Dale·1995·Neuroscience Letters

Abstract

The neuropathological hallmarks of Alzheimer's disease (AD) are amyloid-containing plaques and neurofibrillary tangles. The main constituent of senile plaques is amyloid beta-peptide (A beta) and in recent years, pathogenic mutations in the amyloid precursor protein (APP) gene have been discovered in some AD families. The APP670/671 mutation, found in a Swedish AD family, has revealed over-production of A beta as one pathogenic mechanism for the development of AD. In the present study we have used an immunoassay to measure A beta levels in cerebrospinal fluid (CSF) from APP670/671 mutation-carriers and non-carriers. A correlation was seen between decrease in A beta levels and duration of disease although no difference was found in levels of A beta between the groups (14.5 +/- 3.3 ng/ml versus 14.9 +/- 2.3 ng/ml).

Integrity signals

Registry

Crossref · 10.1016/0304-3940(95)12059-d

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Lannfelt, L., Basun, H., Vigo-Pelfrey, C., Wahlund, L.-O., Winblad, B., Lieberburg, I., & Schenk, D.
Affiliations
Karolinska Institutet (SE)
Corresponding author
Lannfelt, Lars
Venue
Neuroscience Letters
Publisher
Elsevier BV
Published
1995-10
Volume
199
Issue
3
Pages
203-206
ISSN
0304-3940 (ISSN-L)
OpenAlex
W2010245335
Cited by
39
References
27
Citations by year
2022: 1 · 2017: 2 · 2016: 1 · 2015: 2 · 2014: 2 · 2013: 2 · 2012: 1
FWCI
0.84
Type
journal article
Language
en
Open access
closed
Locations
  • Neuroscience Letters (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
amyloid-beta, cerebrospinal fluid, Alzheimer's disease, amyloid plaques, disease duration, cerebrospinal fluid biomarkers
MeSH terms
Adult, Aged, Alzheimer Disease, Family, Genotype, Humans, Middle Aged, Mutation, Sweden, Time Factors, Amyloid beta-Protein Precursor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review